Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Protease Stories

2011-11-16 16:40:00

NEW YORK, Nov. 16, 2011 /PRNewswire/ -- Oligomerix, Inc. presented results at the Society for Neuroscience meeting in Washington D.C. which demonstrated that tau protein forms neurotoxic oligomers with a newly discovered enzymatic function. This proteolytic function results in tau's self-fragmentation and in the degradation of other proteins suggesting a mechanism for its neurotoxic mode-of-action. Furthermore, certain tau oligomer species that contained the highest level of activity also...

2011-11-14 15:15:00

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain. Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity...

2011-11-03 05:00:00

MENLO PARK, Calif., Nov. 3, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cathepsin protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, today announced the appointment of David B. Karpf, M.D. as chief medical officer. Dr. Karpf has more than 20 years of experience in guiding the clinical development of novel therapeutics, both at growing biotechnology firms and within large...

2011-09-27 15:02:32

Researchers at the Perelman School of Medicine at the University of Pennsylvania, Monash University, and Virginia Tech have used a set of novel inhibitors to analyze how the malaria parasite, Plasmodium falciparum, uses enzymes to chew up human hemoglobin from host red blood cells as a food source. They have validated that two of these parasite enzymes called peptidases are potential anti-malarial drug targets. The research appeared in the Aug. 15 early online issue of the Proceedings of the...

2011-07-11 19:44:41

New tool reveals mutations that cause HIV-drug resistance Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new tool has been developed to help predict the location of the mutations that lead to drug resistance. First discovered in 1995, protease inhibitor drugs have dramatically reduced the number of AIDS deaths. Taken in...

2011-04-12 14:30:45

A molecule that lies dormant until it encounters a cancer cell, then suddenly activates and rouses the body's immune system to fight cancer cells directly, marks the latest step in scientists' efforts to tap the body's own resources to fight the disease. The developers of the technology at the University of Rochester Medical Center dub it the "Pacman strategy" because it hinges upon molecular machines produced in abundance by tumors to chew through and gobble up particular chains of...

2011-04-11 16:00:45

Virtually all processes in the human body rely on a unique class of proteins known as enzymes. To study them, scientists want to attach these molecules to surfaces and hold them fast, but this can often be a tricky undertaking. Now Jinglin Fu and his colleagues at the Biodesign Institute at Arizona State University have developed a superior method for immobilizing enzymes on surfaces, deftly controlling their orientation, improving their efficiency and rendering them more stable. The group's...

2011-04-07 21:56:49

Chemical engineers at UC Santa Barbara expect that their new process to create molecular probes may eventually result in the development of new drugs to treat cancer and other illnesses. Their work, reported in the journal Chemistry & Biology, published by Cell Press, describes a new strategy to build molecular probes to visualize, measure, and learn about the activities of enzymes, called proteases, on the surface of cancer cells. Patrick Daugherty, senior author and professor of...

13db87efc46c9c277fee146fb66ca144
2011-02-02 10:06:31

With the number of norovirus infection cases rising across the country, scientists from the University of Southampton have successfully crystallized a key norovirus enzyme, which could help in the development of a norovirus treatment. Noroviruses are recognized world-wide as the most important cause of epidemic nonbacterial gastroenteritis (stomach bugs) and pose a significant public health burden, with an estimated one million cases per year in the UK. In the past, noroviruses have also been...

2010-12-16 07:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders. "We are very encouraged by the progress made to date in our...